

Neuropsychiatric aspects of Huntington's disease

J S Paulsen, R E Ready, J M Hamilton, M S Mega, J L Cummings

Abstract

Objective—Neuropsychiatric symptoms are common in Huntington's disease and have been considered its presenting manifestation. Research characterising these symptoms in Huntington's disease is variable, however, encumbered by limitations within and across studies. Gaining a better understanding of neuropsychiatric symptoms is essential, as these symptoms have implications for disease management, prognosis, and quality of life for patients and caregivers.

Method—Fifty two patients with Huntington's disease were administered standardised measures of cognition, psychiatric symptoms, and motor abnormalities. Patient caregivers were administered the neuropsychiatric inventory.

Results—Ninety eight per cent of the patients exhibited neuropsychiatric symptoms, the most prevalent being dysphoria, agitation, irritability, apathy, and anxiety. Symptoms ranged from mild to severe and were unrelated to dementia and chorea.

Conclusions—Neuropsychiatric symptoms are prevalent in Huntington's disease and are relatively independent of cognitive and motor aspects of the disease. Hypothesised links between neuropsychiatric symptoms of Huntington's disease and frontal-striatal circuitry were explored. Findings indicate that dimensional measures of neuropsychiatric symptoms are essential to capture the full range of pathology in Huntington's disease and are vital to include in a comprehensive assessment of the disease.

(*J Neurol Neurosurg Psychiatry* 2001;71:310-314)

Keywords: Huntington's disease; neuropsychiatry; dementia

Huntington's disease is characterised by a triad of symptoms including motor disturbance, cognitive impairment, and psychiatric features. Although it is well established that psychiatric symptoms are common in Huntington's disease¹⁻⁵ research and clinical emphases have been on motor and cognitive aspects of the disorder. Reconsideration of the psychiatric manifestations of the disease is warranted. Firstly, psychiatric disturbances are most strongly associated with stress, disability, and placement decisions.²⁻⁶ Secondly, there is evidence that brain changes precede the traditional clinical diagnosis and psychiatric manifestations may predate motor signs by a decade.⁷⁻⁸ Finally, clinical trials are underway to slow Huntington's disease progression in clinically affected

patients with plans to treat "preclinical" patients imminent. Careful study of neuropsychiatric symptoms associated with Huntington's disease is essential to help distinguish features that are pathognomonic from behaviours that are sensitive but not specific of the disease.

Models emphasising the role of the basal ganglia in neuropsychiatric disorders have been described over the past several decades.⁹⁻¹¹ One recent overview suggests that because the earliest pathological changes in Huntington's disease are in the associative portions of the striatum, the behaviours first affected by disease may be cognitive and psychiatric, rather than motor.¹²⁻¹³ Indeed, reviews of psychiatric symptoms in Huntington's disease have suggested that depression, apathy, aggression, and disinhibition are common and suicide rates are over four times those of the general population.¹⁴ Previous studies have used an array of data collection methods, however, and standardised uniform assessment of psychiatric features in Huntington's disease is lacking. The purpose of the current study is to use the well established neuropsychiatric inventory (NPI¹⁵) to better characterise psychiatric symptoms in the disease.

Methods

SAMPLE

Participants were 52 consecutive patients with Huntington's disease recruited from the Huntington's Disease Clinical Research Program at the University of California at San Diego (n=29) and from the University of Iowa Huntington's Disease Society of America Center of Excellence (n=23). The diagnosis was made by a senior staff neurologist based on the presence of an unequivocal movement disorder in a person with a family history of Huntington's disease. All diagnoses were confirmed by DNA analysis for CAG expansion in the IT15 region of chromosome 4.¹⁶ All consecutive persons with an unequivocal diagnosis attending the UCSD Huntington's disease clinic between 1994 and 1997 or attending the University of Iowa Huntington's disease clinic between 1997 and 1999 were approached for inclusion in the study. No patient refused participation in the study. Four patients were excluded from the study for the following reasons: (a) having a medical illness other than Huntington's disease (n=1); (b) having a history of head trauma with loss of consciousness (n=1); and (c) having an age of onset younger than 18 (n=2). Patients were 52% women with a mean age of 45.5 (SD 11.7) years (range 26-78) and a mean of 13.3 (SD 2.3) (range 6-17) years of education. Duration of disease (number of years since diagnosis) ranged from 0 to 20 years (mean 4.7 (SD 4.4)). Age of onset of illness ranged from

Department of
Psychiatry, The
University of Iowa,
2880 JPP, 200 Hawkins
Drive, Iowa City, IA
52242, USA
J S Paulsen

Department of
Neurology
J S Paulsen

Department of
Psychology
J S Paulsen
R E Ready

Department of
Psychiatry, UCSD
School of Medicine,
San Diego, CA, USA
J M Hamilton

Department of
Psychology, SDSU,
San Diego, CA, USA
J M Hamilton

Department of
Neurology, UCLA
School of Medicine,
Los Angeles, CA, USA
M S Mega
J L Cummings

Department of
Psychiatry
J L Cummings

Department of
Biobehavioral Sciences
J L Cummings

Correspondence to:
Dr J S Paulsen
jane-paulsen@uiowa.edu

Received 12 June 2000 and
in revised form
30 January 2001
Accepted 12 March 2001

25 to 57 with a mean of 43.1 (SD 9.6). There were no juvenile onset cases included in this study. Mini mental state examination¹⁷ (MMSE) scores ranged from 7 to 30 (mean 24.34 (SD 4.38)), and Mattis dementia rating scale¹⁸ (DRS) scores ranged from 63 to 142 (mean 122 (SD 15.6)). Total chorea scores (assessed with the unified Huntington's disease rating scale¹⁹ (UHDRS)) ranged from 0 to 26 (mean 12.4 (SD 7.4)). Over 79% of patients were taking no medication (n=41). Four patients were taking a selective serotonin reuptake inhibitor (SSRI) and a typical neuroleptic drug, although dosages of the neuroleptic drug were very low in every case (<5 mg). One patient was taking an atypical neuroleptic drug. Four patients were taking SSRIs only and one patient was taking trazodone at bedtime for sleep. No patients were taking tetrabenazine. Analyses conducted with and without the subsample of patients taking psychotropic medications did not differ.

PROCEDURE

Huntington's disease caregivers (n=52) were interviewed with the neuropsychiatric inventory¹⁵ (NPI) by JSP or a trained research assistant. The NPI assesses the frequency (four point rating scale) and severity (three point scale) of 10 neuropsychiatric disturbances (delusions, hallucinations, agitation, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor behaviour), and a score from 0 to 12 was obtained for each scale by multiplying frequency by severity. An NPI total score was calculated by summing ratings for all symptoms. The NPI offers advantages over previous psychiatric research in Huntington's disease; it is standardised, is not influenced by normal aging, it is used to characterise various neurological disorders,²⁰⁻²² and it is used as a measure of treatment response²³ and in investigations of the biological correlates of neuropsychiatric symptoms. Informant reports of psychiatric symptoms in patients with neurodegenerative disease are commonly used and have been found to agree significantly with self reports.²⁴

Patients were administered the DRS and MMSE cognitive screening tests and the UHDRS as a measure of chorea severity. Scores on the MMSE were unavailable for two patients. After complete description of the study to the patients and caregivers as approved by the institutional review boards of both universities, informed consent was obtained.

Neuropsychiatric symptoms were not normally distributed. Therefore, all analyses used non-parametric tests. Specifically, Spearman correlation coefficients were used to examine associations between factors, and Mann-Whitney *U* tests were used for all comparisons of means. Due to the many analyses, a significance level of 0.01 was selected to control for multiple comparisons and to guard against type I errors.

Table 1 Descriptors of NPI neuropsychiatric symptoms in Huntington's disease

NPI Scale	Frequency*	Mean†	SD
Dysphoria	69.2	3.12	3.46
Agitation	67.3	2.88	3.32
Irritability	65.4	2.63	3.11
Apathy	55.8	2.79	4.02
Anxiety	51.9	1.96	3.14
Disinhibition	34.6	1.29	2.77
Euphoria	30.8	1.04	2.27
Delusions	11.5	0.75	2.63
Aberrant motor	9.6	0.60	2.18
Hallucinations	1.9	0.23	1.66

n=52.

NPI=Neuropsychiatric inventory.

*Per cent of patients with HD with an NPI scale score ≥ 1 .

†Mean scores are averages of frequency \times severity ratings.

Results

NEUROPSYCHIATRIC SYMPTOM PREVALENCE

Only one patient did not exhibit any neuropsychiatric symptoms. The most often endorsed symptoms were dysphoria (69.2%), agitation (67.3%), irritability (65.4%), apathy (55.8%), and anxiety (51.9%). These symptoms also had the highest mean scale scores, which reflect frequency and severity ratings. Delusions (11.5%), aberrant motor behaviour (9.6%), and hallucinations (1.9%) were the least prevalent and had the lowest frequency by severity mean ratings (table 1).

ASSOCIATIONS OF NPI WITH DEMOGRAPHIC AND DISEASE MEASURES

The total NPI score was negatively correlated with years of education ($r=-0.37$). Mann-Whitney *U* tests comparing symptom means in male and female patients showed no significant differences. Age was negatively correlated with disinhibition ($r=-0.41$) and delusions ($r=-0.36$). Illness duration and chorea severity were not significantly associated with any NPI scores (table 2).

Neither measure of dementia severity (MMSE, DRS) was significantly correlated with neuropsychiatric symptoms (table 2). The DRS initiation and perseveration subscale showed a significant positive correlation with delusions ($r=0.36$). DRS attention was positively correlated with NPI aberrant motor behaviour ($r=0.37$) and dysphoria ($r=0.41$). DRS conceptualisation was positively correlated with aberrant motor behaviour ($r=0.37$). DRS supermarket verbal fluency was positively correlated with delusions ($r=0.38$).

NEUROPSYCHIATRIC SYMPTOM

INTERCORRELATIONS

Intercorrelations with the NPI scale were investigated to assess associations among symptoms and to determine if symptom associations found in other neuropsychiatric populations were replicated. Nine significant symptom associations were found (table 3). The high correlation ($r=0.81$) between irritability and agitation suggests that these two scales are essentially measuring the same construct in this sample of patients with Huntington's disease.

Three of the significant NPI symptom associations (agitation and irritability, anxiety and dysphoria, disinhibition, and irritability) were

Table 2 Correlations between NPI neuropsychiatric symptoms and motor and cognitive measures for patients with HD

NPI Scale	DRS Subscales							
	Chorea	MMSE†	DRS‡	Attention	Conceptualisation	Construction	Initiation and perseveration	Memory
Agitation	-0.02	-0.09	-0.11	-0.15	-0.13	0.02	-0.10	-0.01
Dysphoria	-0.18	0.11	0.30	0.41**	0.25	-0.21	0.29	-0.05
Irritability	-0.14	-0.09	-0.08	-0.23	-0.18	-0.08	0.01	-0.00
Anxiety	0.11	0.06	0.09	0.13	0.11	-0.01	0.06	-0.03
Apathy	-0.12	-0.15	-0.07	0.01	-0.12	-0.16	0.04	-0.17
Euphoria	0.17	-0.08	0.06	-0.07	-0.07	0.09	0.09	0.10
Disinhibition	0.05	0.01	-0.10	-0.24	-0.23	-0.09	0.04	0.04
Delusions	-0.23	0.24	0.22	0.06	-0.07	0.09	0.36**	0.22
Aberrant motor	0.12	0.09	0.24	0.37**	0.37**	-0.15	0.18	-0.01
Hallucinations	-0.12	0.21	0.15	0.15	0.09	0.11	0.20	-0.12
NPI Total	-0.03	0.01	0.04	0.03	-0.03	-0.12	0.11	-0.02

NPI=Neuropsychiatric inventory; DRS=Mattis dementia rating scale; MMSE=mini mental state examination; HD=Huntington's disease.

†n=50; ‡n=52.

**p < 0.01.

Table 3 NPI neuropsychiatric symptom correlations in Huntington's disease

NPI Scale	Agitation	Dysphoria	Irritability	Anxiety	Apathy	Euphoria	Disinhibition	Delusions	Aberrant Motor
Dysphoria	0.26								
Irritability	0.81*	0.20							
Anxiety	0.41*	0.40*	0.43*						
Apathy	0.09	0.14	0.14	-0.05					
Euphoria	0.31	0.10	0.25	0.25	-0.08				
Disinhibition	0.38*	0.22	0.37*	0.34	0.08	0.30			
Delusions	0.08	0.17	0.21	0.27	0.09	0.02	0.40*		
Aberrant motor	-0.01	0.31	0.07	0.28	0.34	-0.05	0.05	0.12	
Hallucinations	-0.17	0.23	0.13	0.24	0.23	-0.09	0.24	0.42*	0.47*

n=52.

NPI=Neuropsychiatric inventory.

*p < 0.01.

also significant ($p < 0.01$) in an Alzheimer's disease ($n = 50$) sample.²² Two significant associations from this sample (apathy and aberrant motor behaviour, dysphoria, and irritability) were not replicated. A significant association between anxiety and agitation found in a sample ($n = 22$) of patients with progressive supranuclear palsy²⁰ was replicated in the Huntington's disease sample.

Discussion

Neuropsychiatric symptoms were common in this Huntington's disease sample, with 98% of patients exhibiting at least one symptom during the previous month. This total incidence is higher than that found in other dementias²² and greater than previously reported in patients with other basal ganglia disorders²¹ also using the NPI. Findings are consistent, however, with other estimates of psychiatric symptoms in Huntington's disease.¹⁻⁴

Dysphoria, agitation, irritability, apathy, or anxiety were present in over 50% of the sample, whereas psychotic symptoms (delusions and hallucinations) and aberrant motor behaviour were rare. Findings from this investigation are consistent with and enlarge past research on neuropsychiatric aspects of Huntington's disease. Specifically, previous findings indicating that affective disorders¹ and symptoms⁴ are common in Huntington's disease were replicated. Apathy and irritability have similarly been found to be evident in about half of patients with Huntington's disease.²⁵

Given the input and output nuclei of the basal ganglia, it is not surprising that rates of neuropsychiatric symptoms are consistently

high in Huntington's disease. The dorsolateral-subcortical circuit projects from dorsal, anterior, and lateral regions of the prefrontal cortex via the dorsolateral head of the caudate, to the ventral anterior and medial dorsal nuclei of the thalamus, and plays a part in complex cognitive processes including working memory, generative behaviours, and the ability to establish and shift from one topic to another. Impairments in these so called "executive functions" also affect various aspects of emotional and behavioural control. For instance, regulatory functions of the circuit (generating and shifting) may alter the appropriate expression of frustration, resulting in apparent irritability and agitation.

The orbitofrontal circuit projects from the anterior and lateral orbitofrontal cortex via the ventromedial caudate nucleus to the ventral anterior and medial dorsal nuclei of the thalamus, and has been associated with disorders including depression and obsessive-compulsive disorder. Most clinical and research reports have found that in virtually all cases, the manifestation of depression was either simultaneous with or after the motor onset of Huntington's disease, suggesting that depression in Huntington's disease is likely due to the disease process. Given that most patients in the current study were prescribed antidepressant medications, it is likely that rates of depression in Huntington's disease are much higher than that reported in the literature.

The medial prefrontal circuit projects from the paralimbic cortical territories (posteromedial orbitofrontal cortex and anterior cingulate) via the nucleus accumbens to the medial dorsal nucleus within the thalamus, and plays a

part in response inhibition. Dysfunction of the medial circuit produces apathy, which has been shown to increase with illness duration in Huntington's disease.^{1 26 27} These findings are consistent with the known degeneration in the disease, progressing from medial to lateral and from dorsal to ventral caudate, possibly impacting on the orbital and dorsolateral circuits before the cingulate circuit. Although apathy was noted in over 50% of patients with Huntington's disease, Litvan *et al*²¹ showed that patients with hypokinetic movement disorders were more likely to demonstrate hypoactive behaviours, such as apathy, whereas patients with hyperkinetic movement disorders (for example, Huntington's disease) demonstrated relatively more hyperactive behaviours (agitation, irritability, and anxiety). This behavioural dissociation is consistent with circuitry involvement, suggesting hypoactive behaviours in persons with cingulate disruption and hyperactive behaviours in people with orbito/dorsal dysfunction.

Associations found between neuropsychiatric symptoms and demographic factors suggested that younger patients were more likely to experience psychotic symptoms and to be disinhibited. Although this finding is consistent with anecdotal reports, the pathophysiology of this association (age and psychosis) is unknown. It is possible that onset of Huntington's disease at an earlier age disrupts frontostriatal circuitry that is not fully developed, resulting in variations in phenotype. Alternatively, other mediating factors likely exist to account for the variability in age of Huntington's disease onset. It is possible that genetic factors influencing age at onset also impact on behavioural phenotype so that mechanisms influencing earlier onset also increase the probability of psychosis. Given that CAG repeat length accounts for only half of the variance in age of onset,²⁸ additional research is needed to better understand Huntington's disease phenotype and onset heterogeneity.

The increased breadth and dimensional assessment of neuropsychiatric symptoms provided by this study showed that patients with Huntington's disease exhibited the full range of symptomatology, from mild to severe, as indicated by NPI frequency and severity ratings. Thus, assessment tools that rely on categorical diagnostic criteria to assess psychiatric aspects of Huntington's disease would likely fail to detect the significant proportion of patients with subthreshold symptoms. Dimensional assessment tools, such as the NPI, may aid in the detection of mild or atypical cases of neuropsychiatric disorders and allow the capture of a full range of symptomatology. Neuropsychiatric assessment at varying degrees of severity also is important because these symptoms can be targeted for intervention and assessment can be used to track change over time during the natural course of the disease, or used to measure response to treatment.

Consistent with previous reports,²⁵ few associations were found between neuropsychiatric symptoms and measures of cognitive or motor

signs. Specifically, the MMSE, total DRS, chorea severity, and disease duration were not significantly correlated with any neuropsychiatric symptom. These findings are consistent with other research²¹ and indicate that behavioural aspects of basal ganglia diseases are often independent of cognitive and motor symptoms, at least early in the disease.

Findings from this study have important implications for clinical neuropsychiatry. The current study suggests that nearly all patients with Huntington's disease experience psychiatric symptoms. In addition, recent research as well as anecdotal evidence implies that psychiatric symptoms may be the first manifestation of disease in up to 79% of patients.⁵ It is likely, then, that clinical neuropsychiatrists may be among the professionals first and most often seen by persons with Huntington's disease. Unfortunately, specific training for behavioural management of patients with Huntington's disease is not typically available in general psychiatry and neurology programmes. Results of this study suggest that the infrequent patient with Huntington's disease should be considered an opportunity for training and that psychiatric assessment should be a standard component of the Huntington's disease evaluation. Excellent references for treatment can be found in Rosenblatt *et al*²⁹ and Leroi and Michalon.³⁰

This study was supported by National Institutes of Mental Health (NIMH) grants (5R29MH5331-05 and 1K02MH01579-01), a National Institutes of Neurological Disorders and Stroke grant (PO410951-G), a Howard Hughes Medical Institute Pilot Grant, and a Carver Medical Research Initiative Grant Award to JSP, a National Institute on Aging (NIA) Alzheimer's Disease Research Center grant, an Alzheimer's Disease Research Center of California grant, and the Sidell-Kagan Foundation to J.L.C.; a NIA grant to MSM (K08 AG100784); a NIMH grant (R03MH59430-01) to J.M.H.; and a NIH/NIA (T32AG00214) fellowship to RER.

- 1 Caine ED, Shoulson I. Psychiatric syndromes in Huntington's disease. *Am J Psychiatry* 1983;140:728-33.
- 2 Cummings JL. Behavioral and psychiatric symptoms associated with Huntington's disease. In: Weiner WJ, Lang AE, eds. *Behavioral neurology of movements disorders*. New York: Raven Press, 1995:179-86.
- 3 Folstein SE, Folstein MF. Psychiatric features of Huntington's disease: recent approaches and findings [review]. *Psychiatric Developments* 1983;1:193-205.
- 4 Shiwach R. Psychopathology in Huntington's disease patients. *Acta Psychiatr Scand* 1994;90:241-6.
- 5 Morris M. Psychiatric aspects of Huntington's disease. In: Harper PS, ed. *Huntington's disease*. London: WB Saunders, 1991:22:81-126.
- 6 Dewhurst K, Oliver JE, McKnight AL. Socio-psychiatric consequences of Huntington's disease. *Br J Psychiatry* 1970;116:255-8.
- 7 Gutekunst C, Li S, Yi H, *et al*. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. *J Neurosci* 1999;19:2522-34.
- 8 Cha JH, Kosinski CM, Kerner JA, *et al*. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. *Proc Natl Acad Sci USA* 1998;95:6480-5.
- 9 Nauta WJ, Mehler WR. Projections of the lentiform nucleus in the monkey. *Brain Res* 1966;1:3-42.
- 10 Swerdlow NR, Koob GF. Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidum circuitry. *Brain Res* 1987;412:233-43.
- 11 Cummings JL. Frontal-subcortical circuits and human behavior. *Neurological Review* 1993;50:873-80.
- 12 Vonsattel JP, Difiglia M. Huntington's disease [review]. *J Neuropathol Exp Neurol* 1998; 57:369-84.
- 13 Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. *Brain Res Rev* 2000;31: 236-50.
- 14 Di Maio L, Squitieri F, Napolitano G, *et al*. Suicide risk in Huntington's disease. *J Med Genet* 1993;30:293-5.

- 15 Cummings JL, Mega M, Gray K, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. *Neurology* 1994;44:2308-14.
- 16 The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993;72:971-83.
- 17 Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975;12:189-98.
- 18 Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In: Bellak L, Karasu TB, eds. *Geriatric psychiatry*. New York, Grune and Stratton, 1976: 77-122.
- 19 The Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. *Mov Disord* 1996;11:136-42.
- 20 Litvan I, Mega MS, Cummings JL, et al. Neuropsychiatric aspects of progressive supranuclear palsy. *Neurology* 1996; 47:1184-9.
- 21 Litvan I, Paulsen JS, Mega MS, et al. Neuropsychiatric assessment of patients with hyperkinetic and hypokinetic movement disorders. *Arch Neurol* 1998;55:1313-19.
- 22 Levy ML, Miller BL, Cummings JL, et al. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. *Arch Neurol* 1996;53:687-90.
- 23 Kaufer D. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. *Dement Geriatr Cogn Disord* 1998;2:8-14.
- 24 Riso LP, Klein DN, Anderson RL, et al. Concordance between patients and informants on the personality disorder examination. *Am J Psychiatry* 1994;151:568-73.
- 25 Paulsen JS, Stout JC, Delapena J, et al. Frontal behavioral syndromes in cortical and subcortical dementia. *Assessment* 1996;3:327-37.
- 26 Paulsen JS, Butters N, Sadek JR, et al. Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. *Neurology* 1995;45:951-6.
- 27 Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. *J Neuropsychiatry Clin Neurosci* 1998;10:314-19.
- 28 Andrew SE, Goldberg YP, Hayden MR. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. *Hum Mol Genet* 1997;6:2005-10.
- 29 Rosenblatt A, Ranen NG, Nance MA, et al. A physician's guide to the management of Huntington's disease. Huntington's Disease Society of America, 1999.
- 30 Leroy I, Michalon M. Treatment of the psychiatric manifestations of Huntington's disease: a review of the literature [review]. *Can J Psychiatry* 1998;43:933-40.

Find out what's in the latest issue
the moment it's published

Email Alerts

Sign up to receive the table of contents by email every month. You can select from three alerts: Table of Contents (full), TOC Awareness (notice only); *Journal of Neurology, Neurosurgery, and Psychiatry* related announcements.

www.jnnp.com